Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Minocycline Hydrochloride

FDA-approved product (capsule, oral), marketed as Amzeeq, Arestin, Dynacin and 7 more.

Registered studies
50+
Lab records
26
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Minocycline Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Conjunctivitis
  • Infection
  • Ornithosis
  • Periodontitis
  • Respiratory tract infectious disorder
  • Rosacea
  • Spotted fever

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Antiinfectives for treatment of acne; Tetracyclines
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF07; WHO ATC J01AA08

Repurposing investigation

Minocycline Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA89.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli89.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis80.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 4 of 4 lab records
  • E. coli: measured active in 3 of 3 lab records
  • K. pneumoniae: measured active in 14 of 17 lab records
  • M. tuberculosis: measured active in 2 of 2 lab records
Open Minocycline Hydrochloride in ChEMBL Registered studies below
Show the 26 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Minocycline Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin

    NCT00240513 · start 2004-08

    Registered record
    Registry ID
    NCT00240513
    Conditions
    Acne Vulgaris
    Interventions
    Minocycline; Minocycline plus tretinoin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2004-08
    Completion
    2006-12
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionMinocycline; Minocycline plus tretinoin
    PhasePhase 4
    Registry statusTerminated

  • Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms

    NCT00243893 · start 2004-07

    Registered record
    Registry ID
    NCT00243893
    Conditions
    Aneurysms; Arteriovenous Malformations
    Interventions
    minocycline; doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-07
    Completion
    2008-10
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAneurysms; Arteriovenous Malformations
    Interventionminocycline; doxycycline
    PhasePhase 1
    Registry statusCompleted

  • Minocycline to Treat Amyotrophic Lateral Sclerosis

    NCT00047723 · start 2003-01

    Registered record
    Registry ID
    NCT00047723
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2007-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    Interventionminocycline
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris

    NCT00145106 · start 2002-03

    Registered record
    Registry ID
    NCT00145106
    Conditions
    Acne Vulgaris
    Interventions
    Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2002-08
    Enrolment
    189

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionTazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
    PhasePhase 4
    Registry statusCompleted

  • Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study

    NCT00203697

    Registered record
    Registry ID
    NCT00203697
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    minocycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    Interventionminocycline
    PhasePhase 3
    Registry statusUnknown